English
Abbott Header Logo
Logo Image

Infectious disease

Get in touch
Infectious disease banner image
Infectious disease banner image
Infectious disease banner image

HIV's rapid evolution leads to genetic variations among different subtypes, differing by 25-35%1 

Eliminating viral hepatitis by 2030 is of national health priority by reducing new infections, and hepatitis-related morbidity and mortality2 

Despite nearing eradication, syphilis has reached crisis levels again, with >200,000 new infections in the US in 20233 

Since 1980, new pathogens causing disease in humans has emerged at a rate of over 3 per year4

Viruses evolve. We monitor them so you don't have to.

Abbott’s Global Viral Surveillance Program has been at the forefront of monitoring HIV and Hepatitis since 1994. 

But as viruses continue to mutate and move around the world faster than ever before, we have expanded our efforts to respond more quickly through the Abbott Pandemic Defense Coalition. 

This first-of-its-kind global network, led by industry, is dedicated to end current epidemics and help prevent future pandemics, giving laboratorians, clinicians, and communities confidence for today and protection for tomorrow.

Abbott Pandemic Defense Coalition map
Abbott Pandemic Defense Coalition map

Transform your laboratory

Through heritage, innovation and understanding, Abbott offers clinical confidence in the fight against infectious diseases.

Guided by Abbott's history of innovation, our experts collaborate to overcome todays' infectious disease challenges and work to continually improve our diagnostic accuracy. Our comprehensive understanding of the rapidly changing infectious disease landscape is key to delivering clinical confidence and brings every person affected closer to the care they need.

HIV

HIV

Diagnosing HIV-positive individuals is critical to connect them to treatment and prevent the ongoing spread of infection so we can help end the HIV epidemic. Abbott's HIV assays enhance lab capabilities to confidently identify the virus, regardless of where it originated.

Hepatitis Solutions

Hepatitis Solutions

Our HAV, HBV and HCV assays are designed to overcome the viral hepatitis diagnostic challenges and help streamline the journey from diagnosis to care, supporting viral hepatitis elimination goals.

Syphilis

In the battle against the syphilis epidemic,  timely and accurate testing plays a crucial role in early detection and treatment. Our automated solution provides accurate results, streamlines the diagnostic process, and enhances efficiency.

TORCH Panel

Confidently detect TORCH infections early in pregnancy to minimize mother-to-child transmission risks. Abbott's TORCH panel provides accurate results and streamlines lab workflows.

SARS-CoV-2 Immunoassays

Coming off the COVID-19 pandemic, SARS-CoV-2 antibody testing can provide additional options to test patients and conduct ongoing research to understand the effects of the disease.

Visit SARS-CoV-2
Core Laboratory Menu and Systems

 

View and download the Core Laboratory menus to see the complete list of available assays and in development assays, categorized by instrument.

Some assays may not be available on all platforms or in all regions.

Alinity Menu
ARCHITECT Menu

 

Hepatitis
Anti-HAV IgG
Anti-HAV IgM
Anti-HBc
Anti-HBc IgM
Anti-HBs
Anti-HCV
HAVAb IgG II
HAVAb IgM
HBsAg
HBsAg Confirmatory

 

Other Infectious Disease
Advise Dx SARS-CoV-2 IgG II Semi-Quant**
Advise Dx SARS-CoV-2 IgM**
SARS-CoV-2 IgG**
Syphilis TP

 

 

 

RETROVIRUS
HIV Ag/Ab Combo

 

TORCH
CMV IgG
CMV IgM*
HSV-1*
HSV-2*
Rubella IgG*
Rubella IgM*
Toxo IgG
Toxo IgM*

 

*In Development. Not commercialy available.

**The Abbott SARS-CoV-2 IgG, AdviseDx SARS-CoV-2 IgM and AdviseDx SARS-CoV-2 IgG II tests run on the Abbott Alinity i platform are for in vitro diagnostic use under the FDA Emergency Use Authorization only. These tests have not been FDA cleared or approved; These tests have been authorized by FDA under an EUA for use by authorized laboratories; These tests have been authorized only for the detection of IgG and the presence of IgM antibodies against SARS-CoV-2, not for any other viruses or pathogens; and These tests are only authorized for the duration of the declaration that circumstances exist justifying the authorizationofemergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. §360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Login or register for a new account on the Lab Central customer portal. Here you can view assay specific package inserts for intended use, important safety information and manage your personalized lab metrics.

Visit Lab Central

A unified approach

Diagnostics at Abbott offers a complete portfolio of integrated solutions including Core Laboratory, Molecular, Point of Care, Rapid Diagnostics and Transfusion Medicine.

Explore diagnostics at Abbott

Explore

Immunoassays

Abbott's high-quality immunoassay menu helps laboratories meet requirements to be reliable, accurate and precise.

Explore Immunoassays

Mild Traumatic Brain Injury

Learn how Abbott has helped physicians evaluate suspected mild traumatic brain injury (mTBI).

Learn about mtbi

Alinity Family

Discover how Alinity uses powerful technology to help redefine and improve operational productivity and confidence in your laboratory.

Get to know Alinity
References
  1. Bbosa, Nicholasa; Kaleebu, Pontianoa,b; Ssemwanga, Deogratiusa,b. HIV subtype diversity worldwide. Current Opinion in HIV and AIDS 14(3):p 153-160, May 2019. | DOI: 10.1097/COH.0000000000000534.
  2. https://www.cdc.gov/hepatitis/media/dvh-strategicplan2020-2025.pdf?CDC_AAref_Val=https://www.cdc.gov/hepatitis/pdfs/DVH-StrategicPlan2020-2025.pdf; Accessed 19 Nov. 2024.
  3. https://www.cdc.gov/sti-statistics/annual/summary.html; Accessed 19 Nov. 2024.
  4. Institute of Medicine Forum on Microbial Threats. Infectious Disease Emergence: Past, Present, and Future.
Logo Image

©2025 Abbott. All rights reserved.

All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. Any photos displayed are for illustrative purposes only. Any person depicted in such photos may be a model. Please read the Legal Notice for further details.

All ARCHITECT analyzers, Alinity hq, CELL-DYN Ruby and CELL-DYN Emerald 22 AL instruments are Class I laser products. ACCELERATOR APS and ACCELERATOR a3600 are Class II laser products.

The Alinity, ARCHITECT and CELL-DYN systems are intended for performing in vitro diagnostic assays on samples of human origin. Read the instructions in the system manuals and labeling and/or reagent instructions carefully.

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.

Do you wish to continue and exit this website?

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

Do you wish to continue and enter this website?

NO